Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

PubWeight™: 4.18‹?› | Rank: Top 1%

🔗 View Article (PMID 28605608)

Published in N Engl J Med on June 12, 2017


Bruce Neal1, Vlado Perkovic1, Kenneth W Mahaffey1, Dick de Zeeuw1, Greg Fulcher1, Ngozi Erondu1, Wayne Shaw1, Gordon Law1, Mehul Desai1, David R Matthews1, CANVAS Program Collaborative Group

Author Affiliations

1: From the George Institute for Global Health, Faculty of Medicine, UNSW Sydney (B.N., V.P.), the Charles Perkins Centre (B.N.), and the Royal North Shore Hospital (V.P., G.F.), University of Sydney, and the Faculty of Medicine, University of New South Wales (B.N.) - all in Sydney; Imperial College London, London (B.N.), and the Oxford Centre for Diabetes, Endocrinology, and Metabolism and Harris Manchester College, University of Oxford, Oxford (D.R.M.) - both in the United Kingdom; the Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA (K.W.M.); the University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (D.Z.); and Janssen Research and Development, Raritan, NJ (N.E., W.S., G.L., M.D.).

Associated clinical trials:

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS) | NCT01032629

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R) | NCT01989754

Articles citing this

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med (2017) 0.99

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med (2017) 0.95

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med (2017) 0.95

Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Curr Diab Rep (2017) 0.75

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4. J Clin Med Res (2017) 0.75

Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Curr Geriatr Rep (2017) 0.75

Diabetes: Lower risk of cardiovascular death with canagliflozin. Nat Rev Cardiol (2017) 0.75

Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetol Metab Syndr (2017) 0.75

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care (2017) 0.75

Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol (2017) 0.75

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. Diabetes Ther (2017) 0.75

Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. Nat Rev Nephrol (2017) 0.75

Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk. Nat Rev Endocrinol (2017) 0.75

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc Diabetol (2017) 0.75

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther (2017) 0.75

Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. Curr Diab Rep (2017) 0.75

Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol (2017) 0.75

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol (2017) 0.75